Prototype (Live)
See how people taper or adjust buprenorphine over weeks and months. Log in to unlock personalized regimen suggestions and interactive charts.
Interactive treatment patterns based on real-world buprenorphine discussions. Experiment with dose schedules, view modeled symptom trajectories, and compare example taper strategies.
*Not medical advice. Placeholder modeling for prototype demonstration.
Overlay expected symptom patterns based on the extraction engine.
Adjust the dose, schedule, or taper speed to preview how changes affect the model. These modifications are not saved to any account — purely for demonstration.
Comparison uses synthetic data — not clinical guidance.
• Regimen patterns are based on extracted trajectories from 68k+ posts.
• Each slider connects to the same modeling engine used for symptom extraction.
• Logged-in users will eventually get personalized recommendations based on
(1) symptoms they report, (2) time on buprenorphine, and (3) their taper goals.
• This mockup is investor-facing — no real PHI or clinical decision support.
Explore how symptoms change across treatment. Log in to view interactive timelines from >60,000 patient reports.
This is a mock-up of a symptom-clustering atlas for opioid withdrawal and buprenorphine treatment. All data shown here is synthetic.
Select a cluster to view associated symptoms.
People report trying these approaches for chronic symptoms during
buprenorphine treatment.
For demonstration. Not medical advice.
Early-warning signals, severity trends, and cross-symptom correlations. Log in as a researcher or clinician to access the full analytics suite.
Clinical-grade insights (mock data). A logged-in physician would view patient trends, regimen adherence, common symptoms, and risk flags.
Ariadne converts patient experience signals into interpretable clinical decision support, validated through a staged retrospective → prospective pathway.
Publicly available patient narratives from online forums.
Domain experts label symptoms, adverse effects, adherence barriers, coping strategies—creating a high-quality training corpus.
Entity extraction + normalization + temporality + negation + distress markers using curated ontologies and model-assisted pipelines.
Identify Remedies Specifically and Repeatedly Described to Have a Narrow Spectrum of Effects
Patient guidance + clinician dashboards.
Ariadne is being validated as a clinical decision support that increases adherence to buprenorphine treatment at 6 months.
Initial D2C marleting as patient guidance, with a clear roadmap to regulated clinical decision support software (CDS) for clinicians.
This prototype is for demonstration/pilot discussions and does not provide medical advice.
Built by clinicians and scientists at the intersection of addiction care, toxicology, and applied AI.
Assistant Professor at Weill Cornell. Clinician-scientist in medical toxicology with experience building clinical decision support and real-world evidence pipelines.
Assistant Professor at Weill Cornell with leadership experience in care innovation, telemedicine, and hospital-at-home operations.
Medical student with startup and commercialization experience.
Ariadne began as an effort to better understand what patients actually experience during opioid withdrawal and recovery, and to turn those insights into practical support tools.
Dr. Chary conceived of applying linguistics and information theory to real-world data to understand patterns of medication use.
Ariadne was conceived to address a gap in the treatment of opioid use disorder. Patients do not keep taking a life-saving medication because of symptoms and barriers to adherence.
Dr. Chary and Mr. Sprouse meet at i4SUD, sponsored by the National Institute on Drug Abuse, and begin collaborating on Ariadne. They are later joined by Dr. Fortenko.
Awarded the NIDA 100K SUD Startup Challenge.
Our prototype is live with 112,000 unique reports, driving 12 recommendations across 10 symptoms.
Test in real-world settings and refine how it supports patients, clinicians, and partner organizations.
We’re building an interpretable clinical decision support platform to improve retention in opioid use disorder treatment. We collaborate with clinics, health systems, payers, researchers, and aligned investors.
Our mission at Ariadne is simple: to help people stay on life-saving treatment by making side-effect management practical, personalized, and reliable. We’re starting with buprenorphine because that’s where the failure rate is highest and the consequences are most severe.
Retention is the key failure mode in buprenorphine care. Ariadne uses real-world patient experience signals to identify dropout risk early, map drivers to evidence-linked interventions, and deliver interpretable outputs suitable for clinical workflow and governance.
Overview of product, market, validation pathway, and pilot plan.
Pitch Deck (PDF)If you prefer, we can share an updated investor memo and data room links.